THE BE T
Multimedia Highlights
From the CardioSource WorldNews YouTube Channel | Scan the QR code to watch the full video
3-Year Results of ORBIT II
Patients with TAVR and a Left Main
Stent: Room Enough for 2 Giants?
TAVR: Good Results Confirmed for
New-generation TAVR Devices
Raj Makkar, MD: “One of the concerns early
on was [the question], ‘Are we going to be
able to access coronary arteries after we put
in this metal cage, which is what TAVR is, with
a valve inside it?’ Of course, today, I think
dealing with coronary obstructions and going
through these metal cages is almost a nonissue.”
Alec Vahanian, MD: “[The LotusTM Valve]
is one of the new devices. It has several
particular advantages: it can be repositioned;
it can be retrieved for more satisfactory
positioning; and it also has a skirt, which is
aiming at decreasing the paravalvular leaks.
There plenty of theoretical—and, point of
fact, real—advantages. What we didn’t know
was the long-term or mid-term follow-up.”
PCI for Cardiogenic Shock: Moving
Forward Despite Disappointing Results
Identifying Better Ways to Diagnose and
Manage Patients with Cryptogenic Stroke
Tanveer Rab, MD: “The paper is an excellent
review of the outcomes to the CathPCI
Registry®. The cardiogenic shock trends
are increasing. I would hope, with modern
technology, that whatever is accessible to
us in the United States—the most advanced
technological country in the world—we would
be able to make a great impact saving lives.
But, unfortunately, that is not the case; that is
disappointing.
Mary Ann Bauman, MD: “What we’re
trying to do is raise awareness about
cryptogenic stroke and trying to determine
the appropriate protocols so that everyone,
wherever you are in this country, will get the
same evaluation, because what we’d like to
do is take cryptogenic stroke, which means
a stroke of unknown cause, and turn it into a
known-cause stroke.”
A Universal Antidote to Reverse
the Anticoagulant Effects of Factor
Xa Inhibitors
Jeffrey W Chambers, MD: “The primary
endpoint was 30 days safety and efficacy;
we met both those end points by significant
margins. Now, we’ve looked at what’s
happened over the past 3 years. You want to
know if your results are good to begin with
and if they hold up over time. Our 3-year
results show that we have a target lesion
revascularization of 7.8%, a cardiac death rate
of 6.7%, and an overall MACE of 23%. Very
good results.”
10
CardioSource WorldNews
Mark Crowther, MD: “It is super important to
have a universal antidote because inhibitors
are becoming more and more frequently
used in clinical practice. They have really
changed the approach to anticoagulation for
patients at high risk of blood clots, including
patients with atrial fibrillation and deep vein
thrombosis.”
April 2016